key: cord-0947730-wqsaogpv
authors: Yanay, Noa Berar; Freiman, Sarit; Shapira, Ma'anit; Wishahi, Samar; Hamze, Munir; Elhaj, Mohamad; Zaher, Maha; Armaly, Zaher
title: Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients
date: 2021-04-20
journal: Kidney Int
DOI: 10.1016/j.kint.2021.04.006
sha: 61fdd8299464420b18abe28eb9ef263a4ac8978f
doc_id: 947730
cord_uid: wqsaogpv

nan

Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients Q1 To the editor: The immune system is profoundly affected by uremia. End-stage kidney disease (ESKD) patients may be more vulnerable to infections and may have suboptimal response to vaccination. 1 For the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 ), patients with ESKD are at increased risk of infection and mortality. [2] [3] [4] The first emergency use authorizations for COVID-19 vaccines were granted by the Food and Drug Administration in December 2020, and clinical trials for the approval of more vaccines are ongoing. However, the representation of patients with chronic kidney disease and ESKD in these trials is low or unreported. 5 The Pfizer BiONTech trial of the BNT162b2 vaccine included 256 patients with renal disease with no further details on the stages of the chronic kidney disease. 6 We investigated dialysis patients and a control group who had completed 2 doses of vaccination with the mRNA BNT162b2 vaccine for anti-spike protein antibody response (LIAISON SARS-CoV-2 S1/S2 IgG; DiaSorin) and observed them for up to 10 weeks (for detailed methods, see the Supplementary Methods).

A total of 160 chronic dialysis patients (127 hemodialysis and 33 peritoneal dialysis) and 132 control group persons were analyzed ( Table 1 ). The median age in the dialysis group was 69 years (interquartile range [IQR], 62-78 years); and for the control group, 50.5 years (IQR, 41-60 years) (P < 0.001). A total of 63% in the dialysis group and 51% in the control group were men (P ¼ 0.022). In the dialysis group, 79% were on hemodialysis and 21% were on peritoneal dialysis. The median dialysis vintage was 3.2 years (IQR, 1.6-5.4 years).

A total of 90% of the dialysis group and 100% of the control group were positive for anti-spike antibodies (P < 0.0001). The median level of anti-spike antibody was 116.5 arbitrary unit (AU)/ml (IQR, 66-160 AU/ml) in the dialysis group and 176.5 AU/ml (IQR, 142-235 AU/ml) in the control group (P < 0.001).

In the dialysis group, in patients aged $75 years, the median anti-spike antibody level was 99.5 AU/ml (IQR, 28.75-139.5 AU/ml); and in patients aged <75 years, the median level was 122 AU/ml (IQR, 72.8-167.0 AU/ml) (P ¼ 0.035) (Supplementary Figure S1 ).

In the dialysis group, we compared the lowest anti-spike antibody level quartile group (antibody level, <3.8-66 AU/ ml) with the highest anti-spike antibody level quartile (160->400 AU/ml): the median age in the lowest quartile was 72 years (IQR, 66.25-81.00 years); and in the highest quartile, 67 years (IQR, 56.25-74.00 years) (P ¼ 0.02). These 2 subgroups did not differ in dialysis modality, dialysis vintage, and gender Q2 distribution (Supplementary Table S1 ).

Six hemodialysis patients (3.75%) and none in the control group developed COVID-19 new infection (confirmed by positive COVID-19 RT-PCR Q3 ) >7 days after completion of the recommended vaccination regimen (P ¼ 0.033). All 6 patients had symptoms compatible with COVID-19 infection. The clinical course was severe for 1 patient, moderate for 3 patients, and mild for 2 patients. All of them recovered (Supplementary Table S2 ). Of these 6 patients, 4 had antispike antibody level in the lowest quartile (<3.8-66 AU/ ml); in other 2 patients, blood samples for antibody level were not obtained before the diagnosis of COVID-19 infection. One patient in this group received long-term steroid treatment and had a history of kidney transplant.

Sixteen patients (10%) in the dialysis group were negative for anti-spike antibodies. When compared with the dialysis patients who were positive for anti-spike antibodies, there was no difference in age, gender, dialysis modality, and dialysis vintage (Supplementary Table S3 ). Two patients in this group had had past kidney transplant, and one patient had active malignancy. None of these patients received recent immunosuppressive therapy. All the patients in this group had adequate dialysis dose: KT/V Q4 $1.2 for the hemodialysis patients and $1.7 weekly KT/V for the peritoneal dialysis patients.

In this study, our main findings are (i) lower response rate to the vaccine, (ii) lower anti-spike antibody level, and (iii) higher rate of COVID-19 infection after vaccination in the dialysis group. We found a lower anti-spike antibody response rate in dialysis patients compared with a control group representative of the general population. In the group of 16 patients with negative antibody response, we did not find a difference in age, gender, dialysis modality, and dialysis vintage when compared with dialysis patients who developed anti-spike antibodies in response to the vaccine. All 16 patients had adequate dialysis dose. Only 3 patients had other medical condition (past kidney transplant and malignancy) that could have contributed to the blunt antibody response. Similar findings of decreased antibody response to vaccination in the dialysis population are reported also for other vaccines 1,7 and may be explained by the aberrations in immune response characterizing ESKD. The median anti-spike antibody level was lower in the dialysis group when compared with the control group. Older age in our dialysis group was associated with lower anti-spike antibody levels. It is not yet clear if higher level of antibodies after COVID-19 infection correlates with better protection, 8, 9 and there are no reports of correlation between the level of antibodies following vaccination and protection from future COVID-19 infection.

Six hemodialysis patients, comprising 3.75% of this group, developed COVID-19 new infection >7 days after completion of the 2-dose vaccination. This rate is higher than that reported (0.043%) of new infection in the BNT162b2 phase 3 clinical trial 6 and is also higher than 0 events in our control group. It is possible that evolving SARS-CoV-2 variants may be associated with different rates of protection of the vaccine, but the participants in both of our groups live in same area and were vaccinated and investigated at the same time. Therefore, different virus variants are less likely to contribute to the between-group difference. The anti-spike antibody levels in patients who developed COVID -19 infection after vaccination were in the lowest quartile. The assumption of a correlation between antibody levels and protection from future COVID-19 infection should be further investigated.

Some important issues remain unanswered: what is the immunogenicity pattern for other vaccines? Should we routinely determine antibody response in dialysis patients following COVID-19 vaccination? Should we give a booster dose(s) when antibody level is low?

Considering the results of our study, and although many limitations related to COVID-19 are expected to ease in the near future, we may consider maintaining physical distancing and other recommended measures in place for protection of the dialysis population.

Our findings are limited by a relatively small number of participants and a short-term follow-up.

Supplementary Methods. Figure S1 . Anti-spike antibody level in dialysis patients, patients aged <75 years and $75 years. Table S1 . Comparisons of dialysis patients in the lowest and in the highest antibody level quartiles. Table S2 . Details of 6 patients with COVID-19 infection after vaccination. Table S3 . Comparison of dialysis patients with negative and positive antibody response. 

Vaccination in chronic kidney disease

Outcomes of patients with end-stage kidney disease hospitalized with COVID-19

COVID-19 related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration

COVID-19 among US dialysis patients: risk factors and outcomes from national dialysis provider

Systematic review of safety and efficacy of COVID-19 vaccines in patients with kidney disease

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation

A highly specific and sensitive serological assay detects SARS-COV-2 antibody levels in COVID-19 patients that correlate with neutralization

Weak correlation between antibody titers and neutralizing activity in sera from SARS-COV-2 infected subjects

Sarit Freiman 2 , Ma'anit Shapira 2,3 , Samar Wishahi 1 , Munir Hamze 4

Rappaport Faculty of Medicine

E-mail: noab@hy.health.gov.il; and Zaher Armaly, Department of Nephrology and Hypertension

International Society of Nephrology